The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...

Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug ...

Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., ...

Eli Lilly said Wednesday it will invest $4.5 billion to build an advanced pharmaceutical drug manufacturing and development ...

U.S. drugmaker Eli Lilly said on Wednesday it will invest $4.5 billion to create a new center for advanced manufacturing and ...

Lilly will add the center to a site in Lebanon, Indiana, where it is already spending about $9 billion to improve ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Eli Lilly & Co. is pouring $4.5 billion into a new manufacturing plant in Indiana to make drugs for future clinical trials, ...

Eli Lilly's blockbuster weight-loss drug is no longer in shortage in the United States, the U.S. Food and Drug Administration ...

England's National Health Services will offer Eli Lilly's weight-loss drug to nearly a quarter million people as part of a ...

The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...